Damora Therapeutics, Inc. (DMRA) Income Statement
DMRA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsDMRA revenue and net income
DMRA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
DMRA quarterly EPS vs estimates
Damora Therapeutics beat the analyst EPS estimate in 2 of the last 5 quarters. Next report: November 5, 2026 (estimate $-0.52).
DMRA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $34,000 | $181,000 | $830,000 | $490,000 | $441,000 | $188,000 | $111,000 | — |
| Gross profit | −$34,000 | −$181,000 | −$830,000 | −$490,000 | −$441,000 | −$188,000 | −$111,000 | — |
| Research & development | $201.2M | $6.4M | $23.8M | $48.2M | $38.5M | $24.6M | $36.5M | $10.1M |
| Sales, general & admin | $9.7M | $10.5M | $12.7M | $13.0M | $13.7M | — | — | — |
| Total operating expenses | $210.9M | $16.7M | $35.6M | $60.7M | $51.8M | $33.4M | $38.9M | $12.9M |
| Operating income | −$210.9M | −$16.9M | −$36.5M | −$61.2M | −$52.2M | −$33.6M | −$39.0M | −$12.9M |
| Interest income | $1.2M | $844,000 | $1.7M | $722,000 | $156,000 | — | — | — |
| Interest expense | — | — | — | — | — | — | — | $3.0M |
| Income before taxes | −$209.8M | −$21.4M | −$38.3M | −$61.6M | −$51.8M | −$34.8M | −$36.5M | −$15.9M |
| Income taxes | $50,000 | $41,000 | — | — | — | — | — | — |
| Net income | −$209.8M | −$21.4M | −$38.3M | −$61.6M | −$51.8M | −$34.8M | −$36.5M | −$15.9M |
| EBITDA | −$209.8M | −$21.2M | −$37.5M | −$61.1M | −$51.3M | −$33.4M | −$38.9M | −$12.9M |
| EPS (diluted) | −$4.57 | −$18.61 | −$33.86 | −$60.76 | −$51.25 | −$1385.14 | −$36.13 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $11,000 | $68,000 | $7,000 | $10,000 | $9,000 | $8,000 | $5,000 | $60,000 | $77,000 | $98,000 | $229,000 | $367,000 |
| Gross profit | −$11,000 | −$68,000 | −$7,000 | −$10,000 | −$9,000 | −$8,000 | −$5,000 | −$60,000 | −$77,000 | −$98,000 | −$229,000 | −$367,000 |
| Research & development | $25.5M | $23.8M | $197.6M | $1.4M | $1.5M | $678,000 | $1.0M | $1.1M | $1.8M | $2.5M | $2.8M | $2.6M |
| Sales, general & admin | $9.5M | $7.0M | $4.1M | $1.7M | $2.0M | $1.9M | $1.7M | $2.7M | — | — | — | — |
| Total operating expenses | $35.0M | $30.7M | $201.7M | $3.2M | $3.4M | $2.6M | $2.7M | $3.8M | $4.5M | $5.6M | $5.7M | $5.5M |
| Operating income | −$35.0M | −$30.8M | −$201.7M | −$3.2M | −$3.4M | −$2.6M | −$2.7M | −$3.8M | −$4.6M | −$5.7M | −$6.0M | −$5.9M |
| Interest income | $4.1M | $3.1M | $1.0M | $42,000 | $50,000 | $74,000 | $228,000 | $146,000 | — | — | — | — |
| Income before taxes | −$30.9M | −$27.7M | −$200.7M | −$3.1M | −$3.4M | −$2.5M | −$6.7M | −$3.9M | −$5.3M | −$5.5M | −$6.5M | −$8.1M |
| Income taxes | $255,000 | $42,000 | $44,000 | — | $4,000 | $2,000 | −$8,000 | $7,000 | $42,000 | — | — | — |
| Net income | −$31.2M | −$27.8M | −$200.7M | −$3.1M | −$3.4M | −$2.5M | −$6.7M | −$3.9M | −$5.3M | −$5.5M | −$6.5M | −$8.1M |
| EBITDA | −$35.0M | −$27.7M | −$200.7M | −$3.1M | −$3.4M | −$2.5M | −$6.7M | −$3.8M | −$5.2M | −$5.4M | −$6.2M | −$7.8M |
| EPS (diluted) | −$0.39 | −$0.81 | $2.31 | −$2.36 | −$2.60 | −$1.92 | −$5.22 | −$3.39 | −$5.00 | −$5.00 | −$5.97 | −$4.99 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in DMRA's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
DMRA financial results
Damora Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $209.8 million. Diluted earnings per share came to −$4.57.
See the DMRA stock overview for the latest quote and news, or the DMRA chart for price history and technical indicators.
DMRA income statement FAQ
Does Damora Therapeutics have revenue?
Damora Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Damora Therapeutics profitable?
No. Damora Therapeutics reported a net loss of $209.8 million in fiscal 2025.
How much does Damora Therapeutics spend on research and development?
Damora Therapeutics spent $201.2 million on research and development in fiscal 2025.
What are Damora Therapeutics's earnings per share?
Damora Therapeutics earned $-4.57 per diluted share in fiscal 2025, compared with $-18.61 a year earlier.
When will Damora Therapeutics report its next earnings?
Damora Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Damora Therapeutics's fiscal year end?
Damora Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.